

U. S. PATENT APPLICATION


Docket No. 15181.027

TO ALL WHOM IT MAY CONCERN:

BE IT KNOWN that WE, Ashley M. Classen and Mark Revenaugh, citizens of the United States of America, residing in the State of Texas and Oregon, respectively, have invented new and useful improvements in a

METHOD AND APPARATUS FOR VETERINARY RF PAIN MANAGEMENT

of which the following is a specification:

| | |
|--|---|
| CERTIFICATE OF MAILING BY "EXPRESS MAIL" UNDER 37 CFR § 1.10 | |
| "Express Mail" mailing label number: EV 125792555 US | |
| Date of Mailing: February 9, 2004 | |
| I hereby certify that the documents indicated above are being deposited with the United States Postal Service under 37 CFR 1.10 on the date indicated above and are addressed to Box Patent Applications, Assistant Commissioner for Patents, Washington, D.C. 20231 and mailed on the above Date of Mailing with the above "Express Mail" mailing label number. | |
| <u>Sarah Horner</u> (name of person mailing paper) | <u></u> SIGNATURE of person mailing paper or fee |

BACKGROUND OF THE INVENTION

1. Field of the Invention:

The present invention generally relates to relief of pain in animals using radio frequency electrical signals and, more particularly, to a method and apparatus for equine pain therapy using RF stimulation and lesioning techniques.

2. Description of the Prior Art:

The management of pain in animals, particularly large animals such as horses, of the family equinadae, has traditionally relied on rehabilitation strategies, pharmacological intervention and the like. Though often effective, such therapies require significant amounts of time during which to recover from the injury or illness that caused the pain. Further, progress in such therapies may be limited by the presence of the pain during exercises or by the affects of the drugs administered to alleviate the pain while attempting to resume normal function. Moreover, for animals such as horses, that participate in competitive events, drug therapies are often impractical because of rules for drug testing that preclude the use of drugs in the management of pain. Another disadvantage of drug therapies is that the effects are short-lived, lasting only as long as the drug is administered. Further, prolonged reliance on drugs can result in an accumulating resistance to the affects of the particular drug and/or a dependency or difficulties in weaning the patient of continued treatment with the particular drug. Thus, there is a need to provide effective long-term management of chronic pain in animals with minimal significant pharmacological intervention.

The use of pulsed radio frequency (PRF) stimulation - i.e., neuromodulation of peripheral nerves - for medical purposes is not new. In humans, PRF has been described as a therapy for transiently deactivating ADC peripheral nerve fibers. The ADC peripheral nerve fibers are exclusively responsible for chronic pain, while leaving nerve fibers for neuromuscular, acute pain, proprioception (sensory reception of stimuli in muscles, tendons and joints), etc. intact. In general, after the site on

the patient's skin is located, aseptically cleansed and desensitized, the peripheral nerve is accessed percutaneously, i.e., through the skin, via a small incision in the skin. The PRF probe is introduced through the incision and applied directly onto the selected peripheral nerve. The PRF energy is regulated as to amplitude, pulse repetition rate and time duration. Also monitored are the impedance of the probe/patient connections and the temperature of the tissues at the probe tips.

However, the use of PRF for pain management in veterinary medicine has not been described heretofore. Several problems must be overcome. One is, while the peripheral nervous systems of animals in principal is very similar to that of humans, the anatomy of animals differs significantly and requires the development of techniques adapted to these anatomical differences. Further, the RF energy parameters that are effective for the treatment of chronic pain in animals are not necessarily the same as used in human PRF therapies. Another is that animals are generally covered with hair, which requires shaving, removal of the natural oils on the skin and antiseptically preparing the skin. This is typically a cumbersome procedure and leaves a bare, unsightly patch of skin until the hair grows back to its previous condition. Moreover, the PRF probes currently available are not well-suited for use with most animals because of size variations and the need for providing a reliable electrical connection to the nerve tissue of animals. Thus, there is a need for PRF apparatus and methods adapted for use in treating chronic pain in animals, as described herein below.

SUMMARY OF THE INVENTION

There is disclosed a method of reducing chronic pain in animals by radio frequency (RF) neuromodulation of peripheral nerves of the animal, comprising the steps of attaching active and dispersive percutaneous probes at respective active and dispersive locations relative to a peripheral nerve of the patient associated with the pain to be reduced; generating a first pulsed RF signal configured according to a first protocol for coupling to the active and dispersive probes via conductive leads, to verify the location of the peripheral nerve; and generating a second pulsed RF signal configured according to a second protocol for coupling to the active and dispersive probes via the conductive leads after the first pulsed RF signal is withdrawn, to modify propagation of pain sensation in the peripheral nerve without ablation thereof, wherein at least the active percutaneous probe includes an RF cannula having a conductive spatulate blade conformably attached to a dorsal side of a curved, blunt-ended tubular tip portion of the RF cannula.

In another aspect there is disclosed an apparatus for reducing chronic pain in animals by radio frequency (RF) neuromodulation of a peripheral nerve of the animal, comprising a generator, for generating pulsed RF signals in at least a first mode and a second mode to be coupled via respective active and dispersive probes to respective active and dispersive locations on an animal patient's body, for reducing chronic pain experienced by the animal without ablation of the peripheral nerve, a set of RF percutaneous probes including at least an active electrode and a dispersive electrode attached to the respective active and dispersive locations on the animal's body, at least the active probe further comprising an RF cannula having a conductive spatulate blade conformably attached along a longitudinal axis to a dorsal side of a curved, blunt-ended tubular tip portion of the RF cannula, and means adapted to connect with the active probe for administering a liquid substance into the tissue of the animal that is in the active location.

In another aspect there is disclosed a radio frequency (RF) cannula, comprising an insulated tubular body for receiving an RF electrode therethrough, a hub at a first end of the tubular body for interfacing with the RF electrode upon its insertion into the tubular body; and a blunt-ended and

1 conductive tubular tip extending from a second end of the insulated tubular body, arcuate
2 approximately along a longitudinal axis of the tubular body and including a conductive spatulate blade
3 having an oval-shaped distal end and conformably attached to a dorsal side of the blunt-ended,
4 conductive and arcuate tubular tip.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates a horse showing locations amenable to treatment for pain reduction through the use of pulsed RF electrical signals applied according to the method and apparatus of the present invention;

Figure 2 illustrates one embodiment of a pulsed RF generator equipped with active and dispersive probes according to the present invention;

Figure 3 illustrates a prior art RF cannula;

Figure 4A illustrates a plan view of one embodiment of an RF cannula modified according to the present invention;

Figure 4B illustrates a partial side view of the embodiment of the modified RF cannula illustrated in Figure 4A;

Figure 5 illustrates a pictorial view of one embodiment of an RF electrode or stylette coupled to a connector via a conductor, for use with the RF cannula of Figure 4 of the present invention;

Figure 6 illustrates one embodiment of a small syringe for use with the RF cannula of Figure 4 of the present invention;

Figure 7 illustrates one embodiment of a syringe equipped with a Luer tip and one embodiment of the RF cannula of Figure 4 of the present invention;

Figure 8 illustrates a pictorial view of one embodiment of active and dispersive probes in use on a patient according to the present invention;

Figure 9A illustrates a first portion of a flow chart of the method of pain reduction using pulsed RF signals according to the present invention;

Figure 9B illustrates a second portion of a flow chart of the method of pain reduction using pulsed RF signals according to the present invention;

Figure 10 illustrates one embodiment of a pulse waveform for use in the method of pain reduction according to the present invention; and

Figure 11 illustrates another embodiment of a pulse waveform for use in the method of pain reduction according to the present invention.

DETAILED DESCRIPTION OF THE INVENTION

Referring to Figure 1, there is illustrated a horse showing some locations amenable to treatment for pain reduction through the use of pulsed RF electrical signals applied according to the method and apparatus of the present invention. The horse 10 is shown having left and right forelegs 12, left and right hind legs 14, a back 16, a withers 18 and hooves 20. Also shown on the horse 10 are the loci for the treatment sites for pain arising in facet joints 22 in paraspinous areas of the back 16, deep flexor tendons 24 and the navicular joint 26 areas in a foreleg 12, and an injury to a high suspensor 28 on the left hind leg 14.

In general the structural features of the nervous system (not shown in Figure 1) of large mammals is similar to that of humans. For example, it is well known that the central nervous system of mammals includes a sympathetic nervous system and a parasympathetic nervous system. The parasympathetic nervous system includes the autonomic nervous system, which regulates the heart, intestines, glands, etc. The sympathetic nervous system includes the peripheral nerves, which typically lie near the surface of the body of the animal and are involved in sensory reception functions such as touch, heat and cold, and pain.

One class of nerve fibers is known as the ADC peripheral nerve fibers, which are responsible for conducting messages of chronic pain. Other peripheral nerve fibers exist for neuromuscular function, acute pain, proprioception (sensory reception of stimuli in muscles, tendons and joints), etc. The present invention concerns the utilization of pulsed RF energy for the treatment of chronic pain in animals through the neuromodulation of the peripheral nerves that are accessible to the application of RF energy through probes placed percutaneously, i.e., through the skin of the animal's body. The term neuromodulation refers to the deactivation of the ADC peripheral nerve fibers that carry the pain messages to the brain. Although the mechanisms involved in the deactivation of the ADC peripheral nerve fibers through neuromodulation are at present not well understood, it is believed that the presence of the carefully controlled, pulsed RF energy produces neurochemical changes at the

1 molecular level in the nerve fiber tissues, which inhibit the transmission of impulses along the nerve
2 fiber and result in a reduction in the sensation of pain.

3
4 Typical injuries that may be treated using this technique include injuries to various
5 musculoskeletal structures, which meet the following criteria: (1) the injury is long term in nature,
6 i.e., chronic, that has persisted for six months or longer; (2) the injury involves structures that are not
7 critical to sustain mechanical soundness of the animal; (3) the injury has been refractory - not
8 responsive - to traditional therapies; and (4) the injury is located in regions where specific peripheral
9 nerves innervate the region. Some examples of specific conditions might include navicular disease,
10 a gradual deterioration of the navicular bone within the hoof; or an injury to the deep flexor tendon
11 where it attaches to the third phalanx. Other examples may include certain cases of degenerative joint
12 disease where the affected joint is innervated by specific and accessible peripheral nerves.

13
14 Another anatomical area of equine patients where neuromodulation using pulsed RF energy
15 may be beneficial is arrears of the back. As with human patients, back problems such as facet joint
16 degeneration, degenerative disc disease and other problems have been successfully treated using this
17 technique. If the specific peripheral nerve can be identified and the RF probe accurately positioned
18 upon the peripheral nerve associated with the pain caused by the underlying injury or disease, these
19 and similar back problems in horses may be successfully treated.

20
21 In comparison to some traditional treatments, such as a carbocaine block (injection of a local
22 anesthetic), neuromodulation achieved through pulsed RF signals differs in at least two ways: (1)
23 whereas carbocaine causes complete inactivation of the nerve fiber, pulsed RF lesioning (the technical
24 term for the type of RF signal that is used, to be described in detail hereinbelow) enables the selective
25 deactivation of specific fibers within the nerve; and (2) whereas carbocaine is effective for
26 approximately one hour, pulsed RF lesioning, in treatments performed to date, appears to be effective
27 for months and, in some cases, years. Other benefits include (3) the elimination of side effects from
28 pharmacological intervention and much-improved capacity for rehabilitation due to the absence of

1 pain. Another benefit, particularly for animals participating in regulated or sanctioned competitive
2 events, include elimination of the risk of disqualifications caused by a negative result in a drug test.
3

4 In adapting the pulsed RF neuromodulation techniques developed for human patients, several
5 problems had to be overcome before these techniques would be suitable for use with equine patients
6 or other large animals. This experience has also indicates that further development may enable
7 extending the pulsed RF treatment regimes to animals of smaller sizes and possibly for the treatment
8 of a broader range of painful conditions in all animals.
9

10 One problem in the prior art that had to be overcome is the presence of hair covering the skin
11 of the animal. This hair requires removal to enable a satisfactory electrical connection to the
12 animal's peripheral nerve system, which includes a ground return path for the signal introduced to the
13 target ADC peripheral nerve fiber. In the conventional prior art method, the skin must be shaved
14 over a large area to permit the attachment of a so-called "grounding pad," a conductive, gel-filled pad
15 connected to a return conductor that provides a low-impedance ground connection through a large
16 surface area. A typical grounding pad for use with bare skin, as used for humans, is approximately
17 eight centimeters wide and fifteen centimeters long and having an effective surface area of
18 approximately 120 square centimeters, or approximately 18.6 square inches. According to the
19 present invention, one solution is the use of two needles, positioned percutaneously through the skin,
20 one or two centimeters apart. The return conductor is then attached to both needles using suitable
21 connectors. Another solution according to the present invention is the use of a specially designed RF
22 cannula that has a broader, oval-shaped tip to provide a greater contact area and a lower Ohmic value
23 when inserted percutaneously through the skin of the animal being treated. Both solutions will be
24 described in detail in the following description.
25

26 Another problem in the prior art to be overcome is to determine the values of the various RF
27 signal parameters that are most suited to animal patients. Parameters such as carrier frequency, pulse
28 repetition rate, pulse duration, pulse amplitude, the amounts of energy, the duration of the signal
29 application, the temperature of the affected tissues and the impedance values of the RF probe contacts

1 all had to be evaluated and adapted to the anatomical characteristics of the equine patient. In the
2 prior art, these signals are provided by RF signal generators such as the model RFG-3C Plus Lesion
3 Generator, manufactured by Radionics, a division of Tyco Healthcare Group LP, Burlington, MA
4 01903. This device is designed for pulsed RF neuromodulation treatment of human patients. While
5 positive results on equine patients have been demonstrated using the RFG-3C and the device is
6 presently being used for equine treatments, some of its parameters must be modified and the range
7 of signal energies expanded to optimize its use with horses. Further improvements in the areas of
8 programmability and automated control, for example, will provide instruments better suited to large
9 animal therapies.

11 Another problem in the prior art is the technique itself. Although all mammalian peripheral
12 nerves are similar in physiology and anatomy, there are significant differences as to size, sensitivity
13 and structure among various species, which limit the adaptability of human treatment techniques to
14 horses. For example, as explained previously, the design of the RF cannula and the grounding
15 techniques had to be modified for use with equine patients. The technique of using such modified
16 probe instruments is also subject to development because of the specific anatomical variations noted
17 hereinabove. Further, though not well understood, variations in microanatomy or neurochemistry
18 appear to give rise to variations in the techniques used.

20 Referring to Figure 2, there is illustrated one embodiment of a pulsed RF generator 40
21 equipped with active 42 and dispersive 56 probes according to the present invention. The active
22 probe 42, also referred to as an active RF cannula 42, includes a tubular tip 44 covered with
23 insulation 45 (typically teflon) along most of its length and a spatulate blade 46 attached to a dorsal
24 side of a portion of the tubular tip 44 not covered by the insulation 45. Attached to the opposite end
25 of the RF cannula 42 is a cannula hub 48, which is configured to receive a connector 50 that
26 terminates an RF signal conductor 52. The signal conductor 52 is a connecting link to an RF signal
27 output terminal 54 of the pulsed RF generator 40. The dispersive probe 56, also referred to as a
28 dispersive RF cannula 56, includes a tubular tip 58 covered with insulation 59 (typically teflon) along
29 most of its length and a spatulate blade 60 attached to a dorsal side of a portion of the tubular tip 58

not covered by the insulation 59. Attached to the opposite end of the dispersive RF cannula 56 is a cannula hub 62, which is configured to receive a connector 64 that terminates an RF ground conductor 66. The ground conductor 66 is a connecting link to an RF ground output terminal 68 of the pulsed RF generator 40.

Continuing further with Figure 2, the pulsed RF generator 40 includes a power switch 70 and an output switch 72, each providing ON / OFF control, and a mode switch 74. The mode switch enables selection of a stimulator mode or a lesioning mode of operation of the pulsed RF generator 40. A stimulator output display 76 provides readouts calibrated in units of volts, Hertz or milliseconds to indicate values of stimulator mode output signals (or parameters). Similarly, a lesion output display 78 provides readouts calibrated in units of watts, volts and milliamperes to indicate values of lesioning mode output signals (or parameters). A temperature display 80 provides readouts calibrated in degrees Centigrade to indicate values of the tip temperature, i.e., the temperature of the tubular tip 44 of the active RF cannula 42 in contact with the tissues of the animal into which the active RF cannula 42 is placed. The readout shown in the illustrated embodiment is 48.0 degrees Centigrade. A set control 82 enables a user to set the maximum value of the tip temperature that will be reached by the heating effect of the pulsed RF energy output from the pulsed RF generator 40. An impedance display 84 provides readouts calibrated in Ohms or KiloOhms (Kohms) to indicate values of the impedance of the electrical connection with the body of the animal measured between the tubular tips 44, 58 of the respective active 42 and dispersive 56 RF cannulas. The readout shown in the illustrated embodiment is shown as 350 Ohms. An auto control switch enables on / off control of a feature of the pulsed RF generator 40 that regulates the RF signal output level provided at the RF output terminals 54, 68 so that the set value of the tip temperature is not exceeded.

Continuing further with Figure 2, the stimulator mode output (parameter) values are set and adjusted using the controls placed just below and indicated by the stimulator output display 76. In the illustrated embodiment, the stimulator output display 76 indicates a pulse repetition rate of 20.0 Hertz (Hz) or 20.0 pulses per second. Amplitude control 88 varies the amplitude in volts of the RF output pulses that are provided at the RF signal output terminal 54 relative to the RF ground terminal

68 of the pulsed RF generator 40. Rate control 90 varies the pulse repetition rate in pulses per second of the output signal. Duration control 92 varies the length of time that the pulse train of RF signal pulses is applied through the active 42 and dispersive 56 RF cannulas to the tissues of the animal. In this embodiment, each individual control 88, 90 and 92 may include a momentary push switch to change the units shown on the stimulator display 76. Thus, for example, momentarily pressing the amplitude control 88 changes the display to show the readout in volts. Similarly, momentarily pressing the rate 90 and duration 92 controls changes the displayed units to, respectively, pulses per second (pulse/sec) or milliseconds. The controls for the stimulator output, the amplitude control 88, rate control 90 and the duration control 92 may include an arrowhead indicator 77 on the display 76, which moves to the unit legend of the display to indicate the selected control and units.

Continuing with Figure 2, the lesion mode output (parameter) values are set and adjusted using the controls placed just below and indicated by the lesion output display 76. In the illustrated embodiment, the lesion output display indicates an output current parameter value of 10.0 milliamperes. Output control 94 varies the power level in watts of the RF output pulses that are provided at the RF signal output terminal 54 relative to the RF ground terminal 68 of the pulsed RF generator 40. Rate control 96 varies the pulse repetition rate in pulses per second of the output signal. Duration control 98 sets a timer, which varies the length of time in seconds that the pulse train of RF signal pulses is applied through the active 42 and dispersive 56 RF cannulas to the tissues of the animal. In some applications this control may enable values measured in units of minutes or other units may be included. The output control 94 in the illustrated embodiment is coupled with an output level range switch 100, which changes the units of measurement shown on the lesion output display 78. Thus, the output level of the lesion output may be indicated in units of watts (W) of power, volts (V) of amplitude, or milliamperes (mA) of current. The lesion mode of the pulsed RF generator 40 is capable of providing stronger signals to the tissues being treated. Therefore, the illustrated embodiment provides the ability to exert precise control over the parameter values being used. It is important to note that the energy levels applied to the patient during pulsed RF neuromodulation are to be kept below those levels that would result in ablation, and hence,

1 permanent damage to the tissues. As in the controls for the stimulator output, the output control 94,
2 rate control 96 and the duration control 98 may include momentary push switches to change the units
3 of the lesion output display 78. Similarly, an arrowhead indicator 79 moves to the unit legend of the
4 display 78 to indicate the selected control and units.

5
6 Referring to Figure 3, which is not drawn to scale, there is illustrated a prior art RF cannula
7 110 having a tubular tip 112 that is insulated with a teflon coating 114 along most of its length. The
8 tubular tip 112 is fabricated of a material which is an electrical conductor. A typical cannula of the
9 type illustrated in Figure 3 is approximately 13 centimeters (13 cm) long overall. The tubular tip 112,
10 which extends approximately 1.0 centimeter (1.0 cm) from the teflon insulated portion 114 and has
11 a diameter of approximately 0.8 millimeter (0.8 mm), includes an orifice 116 for introducing a fluid
12 substance into the tissues into which the cannula 110 is inserted. The fluid substance, such as an
13 anesthetic, is forced through the tubular tip 112 and the orifice 116 at predetermined times during a
14 procedure using the cannula 110 as will be described hereinbelow. The tubular tip 112 further
15 includes a blunt end 118, which is typically formed to close the end of the tubular tip 112 in a smooth
16 manner. The exposed portion of the tubular tip 112 of the illustrated embodiment is slightly curved
17 about a radius of approximately 2.5 cm through an arc of approximately 20 to 30 degrees to facilitate
18 insertion and placement into the tissues of the human patient being treated. The opposite end of the
19 prior art RF cannula 110 includes a cannula hub 120 having a cylindrical receptacle portion 122 for
20 receiving a thin wire electrode or, typically, the tip of a syringe, neither of which is shown in Figure
21 3 but will be described hereinbelow. The hub 120 includes a lip extension 124 that encircles the
22 receptacle end 122 of the hub 120 and is used to threadingly mate with a device having a Luer tip
23 receptacle (not shown). The illustrated prior art RF cannula is similar to a type C-1010BR, 20 gauge
24 "curved blunt radiofrequency cannula" having a 10 cm length and a 10 mm active tip, which is
25 distributed by Precision Medical Engineering, Middleton, MA 01949.

26
27 Referring to Figure 4A, which is not drawn to scale, there is illustrated a plan view of one
28 embodiment of an RF cannula modified according to the present invention. The RF cannula 130
29 includes a tubular tip 132 that is insulated with a teflon coating 134 along most of its length. The

tubular tip 132 is fabricated of material that is an electrical conductor. An RF cannula of the type illustrated in Figure 4A is approximately 13 centimeters (13 cm) long overall. The tubular tip 132, which extends approximately 1.0 centimeter (1.0 cm) from the teflon insulated portion 134 and has a diameter of approximately 0.8 millimeter (0.8 mm), includes an orifice 136 for introducing a fluid substance into the tissues of an equine patient into which the RF cannula 130 is inserted. The fluid substance, such as an anesthetic, is forced through the tubular tip 132 and the orifice 136 at predetermined times during a procedure using the RF cannula 130 as will be described hereinbelow. The tubular tip 132 further includes a blunt end 138, which is typically formed to close the end of the tubular tip 132 in a smooth manner. The exposed portion of the tubular tip 132 of the illustrated embodiment is slightly curved about a radius of approximately 2.5 cm through an arc of approximately 20 to 30 degrees to facilitate insertion and placement into the tissues of the equine patient being treated.

The RF cannula 130 illustrated in Figure 4A includes a modification to the exposed end of the tubular tip 132. Attached to a dorsal side (see Figure 4B) of the exposed end of the tubular tip 132 is a spatulate blade 140. The spatulate blade 140 is a flat, blade-shaped extension conformably attached to the dorsal side of the tubular tip 132 so that it also is slightly curved to approximately the same radius as the exposed portion of the tubular tip 132. Notice also that the spatulate blade 140 is on the opposite side of the tubular tip 132 from the orifice 136. Further, the spatulate blade 140 has a width across the widest part of approximately 2.0 mm and the rounded, oval - shaped end 142 extends past the blunt end 138 of the exposed portion of the tubular tip 132 for the illustrated embodiment. The end 142 of the RF cannula 130 is not limited to an oval shape. Generally, any shape may be used; preferably the shape of the end 142 should not include sharp edges or points. The opposite end of the RF cannula 130 includes a cannula hub 144 having a cylindrical receptacle portion 146 for receiving a thin wire electrode or, typically, the tip of a syringe, neither of which is shown in Figure 4A but will be described hereinbelow. The hub 144 includes a lip extension 148 that encircles the receptacle end 146 of the hub 144 and is used to threadingly mate with a device having a Luer tip receptacle (not shown).

1 Referring to Figure 4B, which is not drawn to scale, there is illustrated a partial side view of
2 the embodiment of the modified RF cannula illustrated in Figure 4A wherein the same reference
3 numbers indicate like structures. Figure 4B shows the slight curvature of the exposed portion of the
4 tubular tip 132 as described hereinabove and the conformably attached spatulate blade 140, which
5 extends past the blunt end 138 of the exposed portion of the tubular tip 132 by approximately 1.0
6 mm.

7
8 Referring to Figure 5, there is illustrated a pictorial view of one embodiment of an RF
9 electrode or stylette assembly 160 coupled to a connector via an insulated conductor, for use with
10 the RF cannula 130 of Figure 4A and 4B of the present invention. The electrode assembly includes
11 a conductive wire electrode 162 secured into a hub 164, which is attached to an insulated conductor
12 166 connected at its opposite end to a connector 168. The hub 164 encloses an electrical connection
13 between the electrode 162 and a conductive wire (not shown) extending within the insulated
14 conductor 166 to the connector 168, to form an electrical circuit with the connector 168, which is
15 inserted into a mating receptacle for the RF signal 54 or ground 68 output terminal on the pulsed RF
16 generator 40. The electrode 162 has a diameter small enough, e.g., 28 or 30 gauge wire
17 (approximately 0.25 mm to 0.35 mm) to be easily inserted into the hollow interior of the tubular tip
18 132 of the RF cannula 130 shown in Figure 4A and 4B. The wire electrode 162 is a little shorter than
19 the tubular tip 132, so that it reaches just past the orifice 136, i.e., it is visible through the orifice just
20 as the wire electrode is fully inserted within the tubular tip 132. The wire electrode 162 enables an
21 electrical connection to be made between the output 54, 68 of the pulsed RF generator and the
22 tubular tip 132, which makes an electrical connection with the tissue of the patient.

23
24 Referring to Figure 6, there is illustrated one embodiment of a small syringe for use with the
25 RF cannula 130 of Figure 4 of the present invention. The small syringe 170 illustrated includes a
26 body 171 having a capacity of approximately 1.0 milliliter (1.0 ml) and an outlet tip 172 sized and
27 configured to fit within the receptacle 146 of the RF cannula of Figure 4A. The small syringe 170
28 may be used for injecting a local anesthetic into the RF cannula 130 during a treatment procedure to
29 be described hereinbelow in conjunction with Figure 9.

Referring to Figure 7, there is illustrated another embodiment of a syringe, this one being equipped with a Luer tip and shown with one embodiment of the RF cannula 130 of Figure 4 of the present invention. The syringe 173 includes a body 174 having a capacity of, e.g., six ml, an outlet tip 176 and a Luer tip 178. The Luer tip 178 is a hollow cylindrical receptacle that partially encloses the outlet tip 176 of the syringe 173 and includes a spiral-shaped ramp 180 disposed around an inside wall of the Luer tip 178. The spiral ramp 180 acts as an internal thread, which permits the lip extension of a mating hub formed on an RF cannula to be inserted and rotated in the manner of a machine screw into the Luer tip 178. For example, referring further to Figure 7, an RF cannula 182 according to the present invention, including a tubular tip 184 having a conformably attached spatulate blade 185 and a hub 186, also has a cylindrical receptacle 188 configured with a lip extension 190 encircling the cylindrical receptacle 188. The RF cannula is slipped over the outlet tip 176 of the syringe 173 and rotated clockwise such that the lip extension engages the spiral-shaped ramp 180, permitting the RF cannula 182 and the syringe 173 to be secured together in a liquid-tight joint when the RF cannula 182 is fully rotated into the Luer tip 178 of the syringe 173. As will be described further hereinbelow, the syringe will be used to inject a carbocaine block anesthetic into the patient tissues during a treatment procedure.

Referring to Figure 8, there is illustrated a pictorial view of one embodiment of active and dispersive probes in use on a patient according to the present invention. A segment 200 of an equine patient's skin is shown in Figure 8 including an RF cannula 202 used as an active probe and a pair of needles 208, 210 used together as a dispersive probe. In lieu of the pair of needles 208, 210, another RF cannula such as the one shown at 202 could be used, located approximately between the locations 212 and 214 on the segment 200 of the patient's skin and connected to the pulsed RF generator's RF ground terminal (see Figure 2) in the same manner as the RF cannula 202. Figure 8 thus illustrates an alternative to a grounding connection provided by an RF cannula used as a dispersive probe.

Continuing with Figure 8, the active probe, RF cannula 202, coupled to the RF signal output 54 of the pulsed RF generator 40 (see Figure 2) via the conductor 206, is inserted into a small incision 204 (the location of this incision will also be called the active probe site 204 during the description

of the procedure illustrated in Figure 9) in the skin as close as possible to the target ADC peripheral nerve location. The incision, made after suitable antiseptic and anesthetic preparation as will be described, is approximately 0.5 cm long (dimension "A") in a typical case. The spatulate blade of the active probe 202 is positioned so that it is just against the ADC peripheral nerve, being careful to avoid nicking or otherwise injuring the fibers along the surface of the nerve bundle. The dispersive probe, here shown as the pair of needles 208, 210, are positioned approximately one or two cm apart (dimension "B"), a distance of approximately 8 to 10 cm (dimension "C") from the incision site for the active probe. The purpose of the dispersive probe is to provide a suitable ground return connection for the RF signal output from the pulsed RF generator 40. Two needles are used, inserted percutaneously after suitable antiseptic and anesthetic preparation, and connected in parallel to ensure that a low impedance connection is provided. In most cases, it has been found that the impedance, as indicated by the impedance readout of the pulsed RF generator 40, should be kept below 350 Ohms for the best results. The needles 208, 210 are coupled to the conductor 226 via respective alligator clips 216, 218 and leads 220, 222, and a coupling hub 224. The conductor 226 is coupled to the RF ground terminal 68 on the pulsed RF generator 40. If an RF cannula is to be used as the dispersive probe, it is placed through an incision in the skin in the same manner as the RF cannula 202 is placed in the incision 204.

Referring to Figure 9A, there is illustrated a first portion of a flow chart procedure 250 of the method of pain reduction using pulsed RF signals according to the present invention. The method begins at a start block 252 wherein the diagnosis has been made and all necessary equipment and personnel are assembled and positioned for convenient use and operation in the treatment space. In step 254, a suitable RF lesion generator such as the pulsed RF generator 40 is prepared by running through a suitable checklist of test routines to verify proper operation. At this point, the parameter values of the pulsed RF signals may be preset to their initial settings, making sure that the output switch 72 is turned off and the amplitude control 88 and the output level control 94 are set to their minimum settings before adjusting any of the other controls. It is important that no signals be applied to the patient until the active and dispersive probes are properly positioned and the electrical impedance verified in the following steps. After the pulsed RF generator 40 is prepared in step 256,

1 the site of the ADC peripheral nerve associated with the painful condition is located on the patient's
2 skin. In many cases this step can be accomplished by palpation of the surface tissues and observation
3 of the reactions of the horse to locate the peripheral nerve of interest. In other cases it may be
4 necessary to employ a fluoroscope to view real time X-ray images after injecting a small amount of
5 contrast media into the tissues to identify the nerve path.

6
7 Continuing with the procedure 250 of Figure 9A, aseptic preparation of the active and
8 dispersive probe sites is performed in step 258. Next, in step 260, the probe sites are desensitized
9 using a carbocaine nerve block applied to the site locations. In step 262, incisions are made at the
10 site locations and RF cannulas are inserted into the incisions at the active and dispersive sites. The
11 active RF cannula 42 must be inserted with special care to properly locate the spatulate blade 46 of
12 the active RF cannula 42 without damaging the peripheral nerve. The spatulate blade 46 is positioned
13 with its tip alongside and in contact with the surface of the peripheral nerve. The dispersive RF
14 cannula 56 is also inserted carefully into the incision so that the spatulate blade 60 is fully in contact
15 with the tissues just beneath the skin in order to make a reliable ground return connection with the
16 pulsed RF generator 40. In an alternative procedure to step 262, instead of using an RF cannula as
17 the dispersive probe, two needles 208, 210 (see Figure 8, described previously) are inserted
18 percutaneously through the skin at locations 212, 214. The electrical connection is then made to the
19 needles 208, 210 using the alligator clips 216, 218 as illustrated in Figure 8 or other suitable
20 connectors attached to the dispersive conductor 226.

21
22 Continuing with Figure 9A, after the active and dispersive RF cannulas are properly placed
23 on the patient in step 262, the active and dispersive RF electrodes are inserted into their respective
24 RF cannulas in step 264 to enable the measurement of the electrical impedance of the connection to
25 the patient. As described previously, the impedance is displayed on the Impedance readout 84 of the
26 pulsed RF generator 40. The reading is satisfactory if it is below approximately 350 Ohms. A higher
27 value indicates excessive impedance, requiring that one or both of the active 42 and dispersive 56
28 probes must be repositioned before the procedure 250 may be resumed. During the application of
29 the pulsed RF signals in the subsequent steps to be described, the electrical impedance should be

1 monitored to ensure that the indicated parameter values for the amplitude or output levels of the
2 pulsed RF signals are accurate. Failure to perform the procedure with the electrical impedance below
3 350 Ohms could result in injury to the patient or a failed result of the treatment.
4

5 In step 266 the pulsed RF generator 40 is set to the Stimulator mode using the mode switch
6 74. This mode is used to determine the sensory threshold of the patient and to locate the correct
7 ADC peripheral nerve fibers involved in the patient's sensation of pain caused by the underlying injury
8 or disease. With the amplitude control 88 set to its minimum setting, the parameter values are set.
9 For treatment of pain associated with a leg or back injury or disease, the settings are as follows: pulse
10 repetition rate = 10 Hz., pulse duration = 10 msec. and the tip temperature limit is set to 48 degrees
11 Centigrade (deg. C.) when treating horses. However, the tip temperature setting may be varied
12 between 43 deg. C. and 55 deg. C. In step 268, the amplitude is gradually increased while observing
13 the responses of the patient to determine the threshold of sensation and whether the affected
14 peripheral nerve has been correctly selected. In a typical equine patient, the amplitude may be in the
15 range of 3 to 6 volts as the threshold of sensation is approached. At decision step 270, a
16 determination is made whether the probe sites are correctly verified before proceeding with the
17 procedure 250. If the determination is negative, the next step performed is step 272, to remove the
18 pulsed RF generator 40 output, and to perform step 274 to recheck the adjustment of the active RF
19 cannula 202 at the active probe site 204 as shown in Figure 8 and repeat the steps 266, 268 and 270.
20 If the result of step 279 is again negative, the procedure should be aborted to determine the cause and
21 restarted with step 254. During step 270, if the result is affirmative, the procedure flows to step 276
22 shown in Figure 9B.
23

24 Referring to Figure 9B there is illustrated a second portion of a flow chart of the method of
25 pain reduction using pulsed RF signals according to the present invention. In step 276, the output
26 amplitude of the pulsed RF generator 40 is reduced using the amplitude control 88 and the active RF
27 electrode (see, e.g., Figure 5, showing the electrode 160) removed from the active RF cannula 202.
28 Next, in step 278, a small syringe (see, e.g., Figure 6) loaded with a carbocaine block solution is
29 attached to the RF cannula 202 and a prescribed amount of the solution is injected into the vicinity

1 of the target ADC peripheral nerve fibers to temporarily (e.g., for approximately one hour) block the
2 sensation of pain associated with the underlying injury or disease. Then, in step 280, the syringe is
3 removed, the active RF electrode is reinserted and the electrical impedance is re-verified.
4

5 In step 282, the pulsed RF generator 40 is set to the Lesioning (stimulation) mode using the
6 mode switch 74. This mode is used to apply regulated levels of RF pulse energy to the affected ADC
7 peripheral nerve fibers involved in the patient's sensation of pain caused by the underlying injury or
8 disease. With the output level control 94 set to its minimum setting, the parameter values are set.
9 For treatment of pain associated with a leg injury or disease, the typical settings may be as follows:
10 pulse repetition rate = 2.0 Hz., pulse duration = 20 msec., the timer is set to 5 minutes and the tip
11 temperature limit is set to 48 degrees Centigrade when treating horses. In some cases the timer may
12 be set to 120 seconds, repeated at three minute intervals for three cycles instead of continuously for
13 five minutes.
14

15 For treatment of pain associated with a back injury or disease, the settings made in step 282
16 may be as follows: pulse repetition rate = 500 Hz., pulse duration = 1.0 msec., the timer for
17 continuous output of 70 seconds and a tip temperature of 80 degrees Centigrade. The Auto switch
18 is set to the ON position The output level is gradually increased until the tip temperature reaches 80
19 degrees Centigrade and thereafter regulated to maintain that tip temperature until the timer interrupts
20 the RF output while the patient responses are being monitored during the preset interval in step 284.
21 In some applications, such as may occur where considerable experience demonstrates the efficacy
22 thereof, the output level may be controlled manually using the output level control 94, which enables
23 user-adjustment of the output level within the range of zero to ten volts (amplitude of the pulse
24 signal), or zero to 50 watts of RF power, or zero to 100 milliamps of current.
25

26 In some cases the protocol of the preset procedure is repeated one or more times. The
27 determination to do so is made in decision step 286. If the procedure is not to be repeated, the flow
28 advances to step 288, wherein the pulsed RF generator output is reduced to zero (if it was manually
29 increased during the procedure), the RF electrodes removed, the RF cannulas removed and the skin

1 cleaned and the small incision wounds treated. Thereafter, the procedure 250 ends at step 290.
2 Returning to decision step 286, if the result of the determination is that the preset procedure is to be
3 repeated, the flow advances to step 292 to await a predetermined amount of time, according to the
4 protocol for the particular treatment, before the procedure 250 is repeated. In such a case, after the
5 prescribed time has elapsed, the flow returns to the start block 252 in step 294. In some cases only
6 a part of the procedure 250 may need to be repeated; in those cases the flow advances from step 294
7 to an insertion point. The insertion point may occur at steps 264 or 276, for example.

8
9 Referring to Figure 10, there is illustrated one embodiment of a pulse waveform for use in the
10 method of pain reduction according to the present invention. A graph is shown, having a vertical axis
11 labeled in amplitude units such as volts or milliamperes and a horizontal axis labeled in time units such
12 as milliseconds. A generalized pulse waveform 302 is defined by parameters such as pulse duration
13 304, represented by the symbol t_p , the amount of time the pulse is held at a non-zero value. The
14 amplitude of the pulse 302 is represented by the symbol E_{p-s} and the period of one cycle of the pulse
15 308 is represented by the symbol T_s . The frequency, or repetition rate 310, represented by the
16 symbol F_s , is the reciprocal of the period 308, or $1 / T_s$. The subscript "s" in the foregoing symbols
17 means that the symbols define parameters of the Stimulator pulse waveforms. In a typical pulse RF
18 generator 40, such as the RFG-3C mentioned previously, the values for F_s are from a one-shot pulse
19 to 200 Hz; for t_p are from 0.1 msec to 1.0 msec; and for amplitude E_{p-s} , selectable from zero to 10
20 volts or, zero to 10 milliamperes in a constant current mode.

21
22 Referring to Figure 11, there is illustrated another embodiment of a pulse waveform for use
23 in the method of pain reduction according to the present invention. The waveform illustrated in
24 Figure 11 represents a signal provided by the pulsed RF generator 40 when operating in the RF
25 Lesioning mode, as set by the mode switch 74. A graph is shown, having a vertical axis labeled in
26 amplitude units such as volts or milliamperes and a horizontal axis labeled in time units such as
27 milliseconds. A generalized pulse waveform 312 is defined by parameters such as pulse duration 314,
28 represented by the symbol t_{p-l} , the amount of time the pulse is held at a non-zero value. The
29 amplitude of the pulse 312 is represented by the symbol E_{p-l} and the period of one cycle of the pulse

1 318 is represented by the symbol T_1 . The pulse frequency, or repetition rate 320, represented by the
2 symbol F_1 , is the reciprocal of the period 318, or $1 / T_1$. The pulsed RF signals output in the
3 Lesioning mode include a carrier frequency, F_c . Thus, the output pulse waveform consists of a
4 modulated, high frequency carrier signal. In the case of the RFG-3c, the carrier frequency, F_c , is 500
5 kiloHertz (500 KHz.). The subscript "1" (the letter 'l') in the foregoing symbols means that the
6 symbols define parameters of the Lesioning pulse waveforms. In a typical pulse RF generator 40
7 operating in the pulsed lesioning mode, such as the RFG-3C mentioned previously, the values for F_1
8 are from 1.0 to 8.0 Hz; for t_{p-1} are from 10 msec to 30 msec; and for amplitude E_{p-1} , selectable from
9 zero to 100 volts or, zero to 999 milliamperes. The maximum output power in Lesioning mode is
10 50 watts. The timer may be set for values from zero to 20 minutes.

11
12 A method and apparatus for reducing chronic pain in animals by radio frequency (RF)
13 neuromodulation of peripheral nerves of the animal has been disclosed. The method, using the
14 disclosed apparatus, comprises the steps of attaching active and dispersive percutaneous probes at
15 respective active and dispersive locations relative to a peripheral nerve of the patient associated with
16 the pain to be reduced; generating a first pulsed RF signal for coupling to the active and dispersive
17 probes to verify the location of the peripheral nerve; and generating a second pulsed RF signal for
18 coupling to the active and dispersive probes to modify propagation of pain sensation in the peripheral
19 nerve without ablation thereof. In one embodiment of the apparatus, the active percutaneous probe
20 includes an RF cannula having a conductive spatulate blade conformably attached to a dorsal side of
21 a curved, blunt-ended tubular tip portion of the RF cannula. In another embodiment of the apparatus,
22 a dispersive percutaneous probe includes a pair of 22 gauge needles connected to ground return
23 conductors. In yet another embodiment of the apparatus, a pulsed RF generator is modified to
24 provide specific outputs adapted to the neuromodulation of peripheral nerves in veterinary patients.

25
26 The foregoing description, when read in conjunction with the attached drawings, describes
27 several preferred embodiments of the present invention to illustrate the principles of the invention.
28 Variations in structure and function of the embodiments illustrated are contemplated that will be

1 apparent to those skilled in the art yet still fall within the scope of the invention set forth in the
2 appended claims.

3